Pre-made Tadocizumab benchmark antibody ( Fab, anti-ITGA2B;ITGB3 therapeutic antibody, Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Tadocizumab benchmark antibody (Fab, anti-ITGA2B;ITGB3 therapeutic antibody, Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-542-1mg	1mg	3090
GMP-Bios-ab-542-10mg	10mg	Inquiry
GMP-Bios-ab-542-100mg	100mg	Inquiry
GMP-Bios-ab-542-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tadocizumab biosimilar, Fab, Anti-ITGA2B;ITGB3 Antibody: Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody
INN Name	Tadocizumab
Target	ITGA2B_ITGB3
Format	Fab
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2005
Year Recommended	2006
Companies	PDL BioPharma;Yamanouchi
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Coronary artery restenosis;Stroke;Thrombosis
Development Tech	na